SMAD3 Host and Tumor Profiling to Identify Locally Advanced Rectal Cancer Patients at High Risk of Poor Response to Neoadjuvant Chemoradiotherapy.
5-fluorouracil
Smad3
immunohistochemistry
neoadjuvant chemoradiotherapy
polymorphisms
predictive markers
rectal cancer
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2021
2021
Historique:
received:
17
09
2021
accepted:
15
11
2021
entrez:
10
1
2022
pubmed:
11
1
2022
medline:
11
1
2022
Statut:
epublish
Résumé
Identifying patients at risk of poor response to neoadjuvant chemoradiotherapy (nCRT) is an emerging clinical need in locally advanced rectal cancer (LARC). SMAD3 is a key player in the chemoradio-resistance phenotype and its expression is both constitutive and locally induced. The aim was to investigate both host (genetic polymorphisms) and tumor SMAD3 profiling to predict response to nCRT. In a group of 76 LARC patients, SMAD3 and phosphorylated-SMAD3 expression was assessed by immunohistochemistry in preoperative tumor tissue. In an expanded study group (
Identifiants
pubmed: 35002714
doi: 10.3389/fphar.2021.778781
pii: 778781
pmc: PMC8740633
doi:
Types de publication
Journal Article
Langues
eng
Pagination
778781Informations de copyright
Copyright © 2021 De Mattia, Canzonieri, Polesel, Mezzalira, Dalle Fratte, Dreussi, Roncato, Bignucolo, Innocente, Belluco, Pucciarelli, De Paoli, Palazzari, Toffoli and Cecchin.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Trends Cancer. 2016 Sep;2(9):495-504
pubmed: 28741478
Pharmacol Ther. 2019 Apr;196:195-203
pubmed: 30529041
Signal Transduct Target Ther. 2021 Jan 8;6(1):8
pubmed: 33414388
Pharmacol Res. 2020 May;155:104745
pubmed: 32145401
Radiat Oncol. 2020 Nov 10;15(1):262
pubmed: 33172475
Gastroenterology. 2017 Jan;152(1):36-52
pubmed: 27773809
Cancer Treat Rev. 2018 Feb;63:156-171
pubmed: 29407455
Cancer Res. 2015 Jun 1;75(11):2232-42
pubmed: 25858148
Front Immunol. 2017 Mar 13;8:229
pubmed: 28348554
Oncotarget. 2016 Apr 19;7(16):22077-91
pubmed: 26956045
Theranostics. 2021 Jan 1;11(3):1345-1363
pubmed: 33391538
Radiother Oncol. 2020 Aug;149:30-37
pubmed: 32387487
Cancers (Basel). 2020 Dec 03;12(12):
pubmed: 33287114
J Clin Oncol. 2019 Dec 1;37(34):3212-3222
pubmed: 31150315
Oncol Rep. 2015 Jan;33(1):185-92
pubmed: 25370208
Cell Biosci. 2019 Dec 2;9:97
pubmed: 31827763
Nature. 2016 Aug 17;536(7616):285-91
pubmed: 27535533
PLoS One. 2016 Jan 22;11(1):e0147343
pubmed: 26799321
World J Surg. 2015 May;39(5):1257-67
pubmed: 25561186
Oncotarget. 2016 Apr 12;7(15):19781-93
pubmed: 26934318
Biochem Biophys Res Commun. 2016 Aug 5;476(4):420-425
pubmed: 27237972
Clin Cancer Res. 2018 Jun 1;24(11):2493-2504
pubmed: 29476019
Ann Gastroenterol Surg. 2019 Apr 29;3(4):356-367
pubmed: 31346574
Future Oncol. 2015;11(21):2911-22
pubmed: 26414153
J Hematol Oncol. 2021 Apr 6;14(1):55
pubmed: 33823905
Lancet Oncol. 2021 Jan;22(1):29-42
pubmed: 33301740
Int J Biol Sci. 2020 Jan 30;16(6):1010-1022
pubmed: 32140069
Cancers (Basel). 2020 Dec 05;12(12):
pubmed: 33291454
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv263
pubmed: 29741565
Radiother Oncol. 2019 May;134:110-118
pubmed: 31005204
Cancer Biol Ther. 2017 Sep 2;18(9):681-693
pubmed: 28799829
Nat Rev Drug Discov. 2012 Oct;11(10):790-811
pubmed: 23000686
J Biochem. 2019 Apr 1;165(4):317-322
pubmed: 30535026
Cancer. 1994 Jun 1;73(11):2680-6
pubmed: 8194005
Crit Rev Eukaryot Gene Expr. 2007;17(4):281-93
pubmed: 17725494